Smoore International Not Listed as Huabao's Main Client

Business by 2FIRSTS.ai

Dec.06.2023

Smoore International Not Listed as Huabao's Main Client

Huabao Shares denies Smoore International as its main client, clarifies on investor platform.

An investor asked on the investor interaction platform: Is Smoore International the company's main client?

Smoore International Not Listed as Huabao's Main Client

Huabao Group (300741.SZ) stated on December 4th on an investor interaction platform that Smoore International is currently not included among the company's main clients.

Also Read:

[1] Smoore Announces FEELM 2.0: Double the Puffs, Half the Cost

[2] Smoore International Reports Decreased Financial Performance in 2023

#Asia #Market #China #smoore #International

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

China Tobacco Regulation Shift：Policy Updates and Market Impact

China Tobacco Regulation Shift：Policy Updates and Market Impact

PMTA Manufacturing Panel Sees Small Firms Warn “Unknown Is Death” as FDA Defends Review Boundaries

PMTA Manufacturing Panel Sees Small Firms Warn “Unknown Is Death” as FDA Defends Review Boundaries

During FDA’s Feb 10 PMTA roundtable (manufacturing controls panel), small ENDS manufacturers warned that uncertainty in manufacturing expectations creates existential financial risk. FDA officials reiterated review flexibility is constrained by statutory and scientific boundaries. The panel debated testing standards, documentation requirements, open-system responsibility, supply chain changes, and software updates—highlighting unresolved PMTA challenges for small manufacturers.

FDA Commissioner Stresses “Predictability” as Science Chief Addresses Industry Uncertainty

FDA Commissioner Stresses “Predictability” as Science Chief Addresses Industry Uncertainty

FDA Commissioner Marty Makary briefly appeared at the February 10 PMTA roundtable, underscoring the importance of regulatory predictability. At the close of the session, Office of Science Director Matthew Farrelly responded to industry concerns over review uncertainty, stating the agency will issue a written summary of feedback, while reiterating that no fixed quantitative risk benchmark governs authorization decisions.

Guam checks 277 eligible retailers in 2025; eight found selling tobacco or disposable vapes to minors aged 16–20

Guam checks 277 eligible retailers in 2025; eight found selling tobacco or disposable vapes to minors aged 16–20

he Guam Behavioral Health and Wellness Center said that out of 277 eligible tobacco retailers inspected in 2025, eight were found selling tobacco or disposable e-cigarettes or vapes to minors aged 16–20, and one retailer failed to display the required “No Sale Under 21” prohibition sign.

Jan.05 by 2FIRSTS.ai

Virginia asks Fourth Circuit to stay order blocking parts of its unauthorized-vape sales law

Virginia asks Fourth Circuit to stay order blocking parts of its unauthorized-vape sales law

Virginia has asked the U.S. Court of Appeals for the Fourth Circuit to stay a district court order that blocks enforcement of certain provisions of a state law restricting the sale of unauthorized vaping products. The district court held the law was preempted to the extent it enforced federal requirements under the FDCA and the Tobacco Control Act.

Jan.21 by 2FIRSTS.ai

The Volume Illusion: Measuring the Future of Nicotine with the Tools of the Past

The Volume Illusion: Measuring the Future of Nicotine with the Tools of the Past

As next-generation nicotine products become economically central rather than marginal, traditional volume-based metrics are increasingly unable to explain consumption, risk, and value. Units designed for a cigarette-based economy struggle to describe systems defined by delivery speed, pharmacokinetics, and adaptive user behavior. Drawing on financial reporting, regulation, and nicotine science, a fundamental question: can the future of nicotine still be measured using the tools of its past?

Feb.09 by Alan Zhao | 2Firsts Perspectives

Korea’s MFDS sets 2026 plan to manage and disclose harmful constituents in tobacco products

Korea’s MFDS sets 2026 plan to manage and disclose harmful constituents in tobacco products

South Korea’s Ministry of Food and Drug Safety (MFDS) said it has established its 2026 work plan to systematically manage harmful constituents in tobacco products and disclose related information under the Tobacco Harmfulness Management Act, which took effect in November 2025.

Jan.16 by 2FIRSTS.ai

Related Topics

Related Read

PMTA Manufacturing Panel Sees Small Firms Warn “Unknown Is Death” as FDA Defends Review Boundaries

PMTA Manufacturing Panel Sees Small Firms Warn “Unknown Is Death” as FDA Defends Review Boundaries

FDA Commissioner Stresses “Predictability” as Science Chief Addresses Industry Uncertainty

FDA Commissioner Stresses “Predictability” as Science Chief Addresses Industry Uncertainty

Guam checks 277 eligible retailers in 2025; eight found selling tobacco or disposable vapes to minors aged 16–20

Guam checks 277 eligible retailers in 2025; eight found selling tobacco or disposable vapes to minors aged 16–20

Virginia asks Fourth Circuit to stay order blocking parts of its unauthorized-vape sales law

Virginia asks Fourth Circuit to stay order blocking parts of its unauthorized-vape sales law

The Volume Illusion: Measuring the Future of Nicotine with the Tools of the Past

The Volume Illusion: Measuring the Future of Nicotine with the Tools of the Past

Alan Zhao | 2Firsts Perspectives

Korea’s MFDS sets 2026 plan to manage and disclose harmful constituents in tobacco products

Korea’s MFDS sets 2026 plan to manage and disclose harmful constituents in tobacco products